Everything You Need to Know About Uplizna Prescribing Information
Uplizna is a medication that is used to treat neuromyelitis optica spectrum disorder (NMOSD). It is an autoimmune disorder that can affect the optic nerves and spinal cord. Uplizna is a monoclonal antibody that targets a protein called aquaporin-4. This protein is found in high levels in the cells that line the optic nerves and spinal cord.
What is Uplizna Prescribing Information?
Uplizna prescribing information contains all the details about the medication. It includes information on the dosage, administration, contraindications, warnings, precautions, and adverse reactions associated with Uplizna. It is important to consult the prescribing information before prescribing or administering Uplizna.
How is Uplizna Administered?
Uplizna is administered as an intravenous infusion. The recommended dose is 300 mg every 4 weeks for the first 5 doses, and then 600 mg every 4 weeks thereafter. Patients should be monitored during and after the infusion for any adverse reactions.
What are the Adverse Reactions Associated with Uplizna?
Uplizna can cause serious adverse reactions, including infusion reactions, infections, and malignancies. Infusion reactions can range from mild to severe and can include symptoms such as headache, fever, chills, and nausea. Patients should be monitored for these symptoms during and after the infusion.
Uplizna can also increase the risk of infections, including serious infections such as pneumonia and meningitis. Patients should be evaluated for any signs of infection before starting Uplizna and should receive appropriate treatment if an infection is present.
There is also an increased risk of malignancies, including breast cancer, in patients taking Uplizna. Patients should be screened for breast cancer before starting Uplizna and should receive appropriate treatment if breast cancer is present.
Who Should Not Take Uplizna?
Uplizna is contraindicated in patients with a history of hypersensitivity reactions to Uplizna or any of its components. It is also not recommended for use in patients with active hepatitis B virus infection, active tuberculosis, or other severe infections.
Conclusion
In conclusion, Uplizna prescribing information is important for healthcare professionals to consult before prescribing or administering Uplizna. It contains information on the dosage, administration, contraindications, warnings, precautions, and adverse reactions associated with Uplizna.
Uplizna is an effective medication for treating NMOSD, but it can cause serious adverse reactions. Patients should be monitored for infusion reactions, infections, and malignancies during and after the infusion. Patients who have a history of hypersensitivity reactions or active infections should not take Uplizna. Consult with a healthcare professional to determine if Uplizna is a suitable treatment option.
